SCHEMBL21232166

SCHEMBL21232166

COC(=O)NC(CCCCC(=O)Nc1ccccc1NC(=O)OC(C)(C)C)C(=O)Nc1cccc(SC)c1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 15/20 0.77
▸ MEF2D Q14814 13/20 0.77
▸ EP300 Q09472 3/20 0.56
▸ HDAC1 Q13547 3/20 0.52
▸ HDAC3 O15379 3/20 0.51
▸ HDAC2 Q92769 2/20 0.51
▸ HDAC10 Q969S8 2/20 0.51
▸ HDAC6 Q9UBN7 2/20 0.51
▸ HDAC7 Q8WUI4 1/20 0.51
▸ HDAC11 Q96DB2 1/20 0.51
▸ HDAC8 Q9BY41 1/20 0.51
▸ HDAC9 Q9UKV0 1/20 0.51
▸ HDAC5 Q9UQL6 1/20 0.51
▸ SIRT5 Q9NXA8 1/20 0.47
▸ GAA P10253 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ NCOR2 Q9Y618 1/20 0.45
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29355554 1.00 HDAC4 (0.77) HDAC4MEF2DEP300HDAC1HDAC3
SCHEMBL21221180 0.93 HDAC4 (0.67) HDAC4MEF2DEP300HDAC1HDAC3
SCHEMBL21232188 0.87 HDAC4 (1.00) HDAC4MEF2DEP300
SCHEMBL29355918 0.87 HDAC4 (1.00) HDAC4MEF2DEP300
SCHEMBL21232393 0.84 HDAC4 (0.80) HDAC4MEF2DEP300HDAC1HDAC3
SCHEMBL21221195 0.81 HDAC4 (0.48) HDAC4MEF2DEP300HDAC1HDAC3
SCHEMBL21232126 0.80 HDAC4 (1.00) HDAC4MEF2DEP300HDAC1HDAC3
SCHEMBL21221170 0.78 HDAC4 (0.49) HDAC4MEF2DEP300
SCHEMBL21221229 0.78 HDAC4 (0.83) HDAC4MEF2DEP300HDAC1HDAC3
SCHEMBL21232159 0.78 HDAC4 (0.79) HDAC4MEF2DEP300HDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11230524-B2 Myocyte enhancer factor 2 (MEF2) modulators STANDARD LLC (US) 2022-01-25 — — US disclosed
US-20190241504-A1 Novel Myocyte Enhancer Factor 2 (MEF2) modulators STANDARD LLC 2019-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230524-B2 Myocyte enhancer factor 2 (MEF2) modulators MEF2D, MYLK2, TNNT2 HDAC4 81/4885MEF2D 1/4885EP300 35/4885
US-20190241504-A1 Novel Myocyte Enhancer Factor 2 (MEF2) modulators MEF2D, MYLK2, MYOF HDAC4 97/4885MEF2D 1/4885EP300 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback